ArticleMedical decision making : an international journal of the Society for Medical Decision Making2025
Modeling Disability-Adjusted Life-Years for Policy and Decision Analysis.
Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tracking global quality of life trajectories in knee osteoarthritis: a population-based long-term analysis.Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study outlines methods for modeling disability-adjusted life-years (DALYs) in common decision-modeling frameworks. Recognizing the wide spectrum of experience and programming comfort level among practitioners, we outline 2 approaches for modeling DALYs in its constituent parts: years of life lost to disease (YLL) and years of life lived with disability (YLD). Our beginner approach draws on the Markov trace, while the intermediate approach facilitates more efficient estimation by incorporating non-Markovian tracking elements into the transition probability matrix. Drawing on an existing disease progression discrete time Markov cohort model, we demonstrate the equivalence of DALY estimates and cost-effectiveness analysis results across our methods and show that other commonly used "shortcuts" for estimating DALYs will not, in general, yield accurate estimates of DALY levels nor incremental cost-effectiveness ratios in a modeled population.HighlightsThis study introduces 2 DALY estimation methods-beginner and intermediate approaches-that produce similar results, expanding the toolkit available to decision modelers.These methods can be adapted to estimate other outcomes (e.g., QALYs, life-years) and applied to other common decision-modeling frameworks, including microsimulation models with patient-level attributes and discrete event simulations that estimate YLDs and YLLs based on time to death and disease duration.Our findings further reveal that commonly used shortcut methods for DALY calculations may lead to differing results, particularly for DALY levels and incremental cost-effectiveness ratios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.